Hideki Suganami

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 20

Top Topics

Bariatric Surgery

Top Venues

Diabetes, obesity & metabolism

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Clinical and translational science

Endocrinology, diabetes & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Tomohiro Kamimura, Neil J Hounslow, Hideki Suganami, Ryohei Tanigawa
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies. Clinical and translational science 17 (8) (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, null null
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, null null
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, null null
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
Tomohiro Kamimura, Neil J Hounslow, Hideki Suganami, Ryohei Tanigawa
Drug-drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open-label, randomized, 6-sequence, 3-period crossover studies. Clinical and translational science 17 (8) (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, null null
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Atsuki Fukushima, Koji Kawakita, Satoshi Kojima, Toka Nakamura, Hideki Suganami, null null
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 262 (8) (2024)
Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, Hiroomi Minami, Satoshi Kojima, Tomoyuki Isobe, Mizuho Kanazawa, Hideki Suganami, null null
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine. Advances in therapy (2023)
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami
Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses. Endocrinology, diabetes & metabolism (2023)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 24 (12) (2022)
Henry N Ginsberg, Neil J Hounslow, Yusuke Senko, Hideki Suganami, Pawel Bogdanski, Richard Ceska, Akos Kalina, Roman A Libis, Tatiana V Supryadkina, G Kees Hovingh
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy. Diabetes care 45 (4) (2022)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Momoko Oe, Takaaki Sato, Yuta Yaguchi, Kazuya Fujihara, Takaho Yamada, Shiro Tanaka, Kohei Kaku, Hirohito Sone
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 23 (7) (2021)
Yasuhiro Matsubayashi, Alkihiro Yoshida, Hideki Suganami, Taeko Osawa, Kazuo Furukawa, Hiroshi Suzuki, Mayuko Harada Yamada, Shiro Tanaka, Kohei Kaku, Yasuhiro Matsubayashi
Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 22 (6) (2020)
Yuichi Sato, Kiyohide Nunoi, Kohei Kaku, Alkihiro Yoshida, Hideki Suganami
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss. Diabetes, obesity & metabolism 22 (2) (2019)
Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes, obesity & metabolism 21 (7) (2019)
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida, Hideki Suganami
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status. Diabetes, obesity & metabolism 21 (7) (2019)
Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami, Shun Ishibashi
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes care 41 (3) (2018)
Motoshi Ouchi, Kenzo Oba, Hideki Suganami, Akihiro Yoshida, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Kohei Kaku
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated". Diabetes, obesity & metabolism 20 (8) (2018)
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin. Diabetes, obesity & metabolism 20 (4) (2018)
Kiyohide Nunoi, Yuichi Sato, Kohei Kaku, Akihiro Yoshida, Hideki Suganami
Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinology, diabetes & metabolism 1 (2) (2018)